Bio-Pharm Archives - 17 중 7 번째 페이지

Celltrion’s Yuflyma Gains FDA Interchangeability with Humira

Yuflyma. [photo=Celltrion] Celltrion’s autoimmune disease treatment Yuflyma can now be used as an interchangeable substitute for Humira in the United States without a physician’s prescription. Celltrion announced on April 14…

Cheon Okhyeon

2025-04-14

GSK Taps ABL Bio’s Brain-Shuttle Tech in $3B+ Deal

ABL Bio. South Korea’s ABL Bio, a biotech company specializing in bispecific antibodies, has signed a major licensing agreement with global pharmaceutical giant GSK for its proprietary blood-brain barrier (BBB)-penetrating…

Won Jonghyuck

2025-04-07

Korea United Pharm Expands Beyond modified drugs to Obesity and Cancer Therapies

Korea United Pharm, widely known for its stronghold in incrementally modified drugs (IMDs), is gearing up for its next growth phase with high-margin therapies, including obesity treatments and anticancer drugs.…

Cheon Okhyeon

2025-04-01

Bukwang Pharmaceutical Pursues Structural Overhaul Through Rights Offering

Bukwang Pharmaceutical which returned to profitability last year, has launched a rights offering to push ahead with a major structural overhaul. The company aims to resolve long-standing issues such as…

Cheon Okhyeon

2025-03-31

Jeil Pharmaceutical Names Han Sang-cheol Co-CEO to Launch 3rd-Gen Leadership

Jeil Pharmaceutical has officially entered a third-generation management era with the appointment of Han Sang cheol as co-CEO. On March 25, Jeil Pharmaceutical announced that its board of directors had…

Cheon Okhyeon

2025-03-25

Celltrion Pharm Achieves Record-Breaking Revenue of KRW 477.8 Billion in 2023

Celltrion Pharm has set a new record for its highest-ever revenue, driven by the growth of key products such as Remsima SC (subcutaneous injection) for autoimmune diseases. On the 17th,…

Cheon Okhyeon

2025-03-17

Samsung Life Science Fund Invests $10 Million in U.S. Alzheimer’s Blood Test Company

Samsung Life Science Fund is investing $10 million in a company developing technology for Alzheimer’s disease diagnostics. Samsung C&T announced on the 13th that it will invest $10 million (approximately…

Cheon Okhyeon

2025-03-13

Celltrion Secures FDA IND for ADC Cancer Therapy…First Step in New Drug Development

Celltrion has taken its first step as a new drug developer. Celltrion announced on the 5th that it has received Investigational New Drug (IND) clearance from the U.S. Food and…

Cheon Okhyeon

2025-03-05

Celltrion’s Bone Disease Biosimilar Wins FDA Approval in the U.S.

Celltrion announced on the 4th that its bone disease treatment biosimilars Stoboclo and Osenvelt—biosimilars of Prolia and Xgeva (active ingredient denosumab)—have received approval from the U.S. Food and Drug Administration…

Cheon Okhyeon

2025-03-04

Celltrion’s Achievement: Remsima Becomes Korea’s First Global Blockbuster Drug

Celltrion's autoimmune disease treatment, Remsima (ingredient: infliximab), has surpassed annual sales of 1.2 trillion KRW, becoming Korea’s first global blockbuster drug. On the 25th, Celltrion announced its consolidated preliminary results,…

Cheon Okhyeon

2025-02-26